neostigmine has been researched along with azathioprine in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (42.86) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 3 (42.86) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Birnberger, KL; Struppler, A | 1 |
Fasshauer, K | 1 |
Benatar, M; Kaminski, HJ | 1 |
1 review(s) available for neostigmine and azathioprine
Article | Year |
---|---|
Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Azathioprine; Cholinesterase Inhibitors; Evidence-Based Medicine; Humans; Myasthenia Gravis; Neostigmine; Oculomotor Muscles; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome | 2007 |
6 other study(ies) available for neostigmine and azathioprine
Article | Year |
---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Therapy of myasthenia (author's transl)].
Topics: Adrenocorticotropic Hormone; Azathioprine; Female; Humans; Infant, Newborn; Infant, Newborn, Diseases; Male; Myasthenia Gravis; Neostigmine; Pregnancy; Prognosis; Pyridostigmine Bromide; Thymectomy | 1976 |
[Therapy of pseudoparalytic myasthenia gravis].
Topics: Ambenonium Chloride; Azathioprine; Humans; Myasthenia Gravis; Neostigmine; Pyridostigmine Bromide; Thymectomy | 1975 |
Treatment of myasthenia--I.
Topics: Adrenocorticotropic Hormone; Azathioprine; Bronchial Neoplasms; Carcinoma; Cholinesterase Inhibitors; Diagnosis, Differential; Ephedrine; Humans; Muscular Diseases; Myasthenia Gravis; Neostigmine; Neuromuscular Junction; Pyridostigmine Bromide; Thymectomy | 1971 |